Lumiracoxib is a non-steroidal anti-inflammatory drug (NSAID) that acts as an inhibitor of COX enzymes with specificity for COX-2. Like other NSAIDs, lumiracoxib exhibits anti-inflammatory, analgesic, antipyretic, and antinociceptive activities. In animal models of metabolic syndrome, lumiracoxib reverses vascular remodeling and inflammation. In animal models with experimental autoimmune encephalitis (EAE, a translational model of multiple sclerosis), lumiracoxib inhibits lymphocyte responses and decreases disease severity; in similar in vitro models, lumiracoxib inhibits T cell proliferation and modulates expression of T-bet, IL-10, and IFN-γ. This compound may also inhibit thromboxane receptors. Additionally, lumiracoxib exhibits some anticancer potential, inducing G0/G1 cell cycle arrest and apoptosis and inhibiting proliferation in non-small cell lung cancer (NSCLC) cell lines.